News

Ourobio takes top honors at Lighthouse Labs Demo Day

Clutching a plush shark, Alec Brewer, the co-founder and CEO of Ourobio, beamed Tuesday from the stage at the Byrd Theatre. The cuddly sea hunter marked his company as winner of a $1,500 cash prize for a “Shark Tank”-style competition at the the Lighthouse Labs Demo Day showcase.

“The cash is critical to us right now,” said Brewer. “We’ve remained entirely bootstrapped up until this point. Every dollar counts. So, we’re very appreciative of the cash prize.”

Ourobio, previously known as Transfoam, is a Charlottesville company that uses engineered microorganisms to turn industrial byproducts into a low-footprint, bio-based polymer. Put more simply, the company takes industrial waste and turns it into a biodegradable plastic-like substance. It is focusing on making the spools used in the consumer 3D printing filament space, but Ourobio’s founders have an eye on consumer food service products manufacturing

Ourobio co-founders Alec Brewer, left, and Kobe Rogers pose with their prize shark at the Lighthouse Labsl Demo Day.

“This plastic uniquely is not only degradable in the soil and dirt, but also degradable in the ocean,” said Brewer. “A lot of biodegradable plastics are incapable of degrading in the ocean. That’s something that sets our specific material apart from the rest and is a very important material for our future.”

Brewer thought the symbolism of the shark prize was fitting considering the company, which grew out of coursework at the University of Virginia, centers on marine sustainability and reducing waste in the ocean and environment. Kobe Rogers, Ourobio’s COO, and Simonne Guenette, the chief technology officer, are the other co-founders. The company is pre-revenue and is in a pre-seed stage.

Brewer was one of nine founders to present at the two-hour event, an annual demonstration for the Lighthouse Labs accelerator and the first to be held in person for two years because of the Covid-19 pandemic.

Joy Polefrone, health innovation consultant for Virginia Commonwealth University Health and one of four judges for the competition, said Ourobio won because Brewer’s pitch was very well defined and set a course for how the company was planning to move forward, articulating both sides of its market — the supplier side and how it was going to scale.

“It’s incredibly technically complicated, and they understand the technical complications of building plastics solutions, as well as the technical complications of creating something from a microbe,” said Polefrone.

The eight other companies at the pitch competition made up the rest of the Lighthouse Labs’ spring 2022 accelerator cohort, all of whom benefitted from a $20,000 equity-free investment.

Read more here.

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related